No ABSSSI would not have been worth the 30M+ dollar price tag for the PIII. IPIX has been able to move forward in trials with three different products and multiple indications with that money. It is a classic mitigation of risk play. This course takes longer but the value of the company will be higher in the long run. It will prove to be the right move.
I don't actively trade anymore so I'm happy to sit on a long term play those in the trading game might prefer a shorter horizon. To each their own...